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Malignant melanoma incidence increases steadily 
all over the world. The number of patients with this pa-
thology had been doubled in the last 20 years. At the 
early stages of melanoma development the patients 
are treated surgically, but the advanced disease is in-
curable [1, 2]. Melanoma research experts consider in-
stability of melanoma cell biological properties among 
the primary reasons of aggressiveness of the tumor 
and its resistance to antitumor drugs. Melanoma cells 
with different metastatic ability can differ significantly 
in their sensitivity to anticancer agents [3–5].
NSC-631570 (Ukrain) is a semisynthetic product 
of thiosulfuric acid and celandine alkaloids (Chelido-
nium majus L.). The drug has cytotoxic and cytostatic 
action on tumor cells in vitro and in vivo due to its ability 
to accumulate in tumor tissue selectively and cause 
cancer cell death but not normal cells death [6, 7]. 
For more than 20 years NSC-631570 had been used 
for benign and malignant tumor treatment [8]. Ukrain-
based monotherapy, and also its usage in combina-
tion with vaccine based on self-restricted autologic 
dendritic cells demonstrated significant therapeutic 
effect in the treatment of experimental В-16 mouse 
melanoma [9, 10].
NSC-631570 monotherapy was successfully intro-
duced into human melanoma therapy in 1996, and has 
been shown to be effective in combination with adjuvants 
[11, 12]. However, melanoma cells of different origin 
possess different sensitivity to Ukrain components [13].
The Toll-like receptor (TLR) agonists are among 
the most promising adjuvants used for more than 
10 years in combined therapy of malignant melanoma. 
Pathogen associated molecules (PAM), such as pep-
tidoglycane, lipopolysaccharide, flagellin, CpG-DNA 
etc. are the natural TLR agonists. It is known that TLR 
are expressed in a broad spectrum of cells and tis-
sues including the effector cells of immune system. 
Stimulation of TLR-dependent immune cell mediates 
activation of inflammatory reactions and increases 
antitumor immunity [14]. TLR are also expressed on 
many tumor cells including melanoma cells [15, 16]. 
The use of natural (PAM) and synthetic TLR1, 2, 4, 
7 and 9 agonists are shown to be effective for mela-
noma treatment [17]. In the present study, the extract 
of S. aureus Wood 46 CPM was used as PAM. TLR6 in a 
complex with TLR1 and/or TLR2 is considered as a 
potential receptor for CPM [18].
The goal of the study was comparative assessment 
of the effect of NSC-631570 (Ukrain) used alone and 
in combination with PAM, on the mitotic cycle and 
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apoptosis of melanoma cells which possess various 
biological properties.
MATERIALS AND METHODS
Cell cultivation, treatment and cell analysis. 
Mouse melanoma MM-4 and ММ-4М2 cell lines were 
obtained from Bank of Cell Lines of R.E. Kavetsky Institute 
of Experimental Pathology, Oncology and Radiobiology, 
National Academy of Sciences of Ukraine. The cells were 
cultured in vitro in Dulbecco modified Eagle medium 
(DMEM, Sigma, USA), supplemented by 10% fetal bo-
vine serum (FBS), penicillin (100 U/mL) and streptomycin 
(100 μl/mL) at 37 °C in 5% CO2 atmosphere.
To study cell growth kinetics, melanoma cells were 
seeded on 24-well plates at a density of 1 x 104 cells 
per well in 1.5 ml of medium containing 10% FBS and 
incubated at standard conditions for 6 days. The num-
ber of viable cells was determined daily with Trypan 
Blue 0.4% staining as described in [19–21].
To test the cytotoxicity of drugs, cells were treated 
at logarithmic phase of growth with Ukrain (Nowicky 
Pharma, Austria) at the concentrations of 20 μg/ml 
and 250 μg/ml for 24–48 h. Staphylococcus aureus 
cytoplasmic membrane extract (CPM), which was kindly 
granted by prof V.K. Pozur (T. Shevchenko Kyiv National 
University), was used as PAM and was added in culture 
medium at the concentrations of 2 μg/ml and 25 μg/ml 
for 24–48 h. Ukrain (20 μg/ml) + PAM (2 μg/ml) and 
Ukrain (250 μg/ml) + PAM (25 μg/ml) were used for 
combined treatment. Solvent was added to the controls.
For a morphologic investigation, cytospin speci-
mens of cells were dried, Pappenheim-stained and 
analyzed using Axiostar Plus microscope (Carl Zeiss, 
Germany) at x 400–1000 magnification.
DNA extraction, gel electrophoresis and flow 
cytofluorimetry were performed as it was described 
earlier [19–21].
RNA isolation and RT-PCR analysis of TAP1 and 
TAP2 mRNA expression. Total RNA was isolated from 
homogenized cells using the “RiboSorb” KIT (AmpliSens, 
Russia). Extracted RNA was transcribed into cDNA 
using M-MuLV Reverse Transc riptase (Fermentas, 
Lithuania) following recommendations of the manu-
facturer. The cDNA concentration was measured and 
2 μl of each cDNA samples were taken for semiquan-
titative analysis. To circumvent false negative results, 
primers detecting the GAPDH gene were used in the 
same reaction tube. Each reaction mixture for PCR 
contained: Taq-buffer with (NH4)2SO4, 2.5 μМ Mg2+, 
0.2 μМ each dNTP, 1U Taq-polimerase (Fermentas, 
Lithuania), 50 μМ of each primer and 2 μl of cDNA. 
Following primers were used: TAP1 primers — forward 
5’GGACTGTCAGCAGCGGCAACC-3’ and reverse 
5’CAAGGCCTTTCATGTTTGAGGG-3’; TAP2 primers — 
forward 5’CAGGATGCAGTGGCCAGGGCG-3’ and reverse 
5’TAGATACACGTCTTTTTCCAGG-3’; GAPDH primers — 
forward 5’GCCAAGGTCATCCATGACAACTTTGG-3’ and 
reverse 5’GCCTGCTTCACCACCTTCTTGATGTC-3’. PCR 
program: initial denaturation step at 94 °C, 4 min, and 
30 cycles (93 °C 35 s, 60 °C 35 s, 72 °C 35 s). PCR pro-
ducts were visualized by electrophoresis in 2% agarose 
gels with ethidium bromide using UV-transilluminator. 
Semiquantitative analysis of the expression level was 
performed in TotalLab TL120 program (Great Britain).
The statistical significance of the differences between 
mean values was assessed by the Student’s t-test.
RESULTS AND DISCUSSION
ММ-4 cell line and ММ-4М2 subline, which were 
used as the models in the experiments, were estab-
lished earlier from transplantable В-16 melanoma 
of C57BL/6 mice [1]. ММ-4 cells have relatively low 
metastatic ability: the cells rarely metastasize spon-
taneously when transplanted intramuscularly or 
subcutaneously, and upon intravenous application 
of 2 х 105 cells at average 10–20 pigmented metasta-
ses will be formed in the lungs of 70–100% of animals.
ММ-4М2 highly metastatic subline was obtained by 
double in vivo passage of ММ-4 cells in C57BL/6 mice: 
the cells were administered intravenously with further 
in vitro recultivation of the largest lung metastases 
that developed after 21 days. After the preparative 
cultivation of metastatic cells, they were intravenously 
administered to mice, and then the cells from large me-
tastases were again recultivated. The cells of newly es-
tablished line possessed much higher metastatic po-
tential than the initial cells: the metastases are formed 
in 100% of animals, their average number reached 
206.6 ± 56 (ranging from 68 to 360). ММ-4М2 cells 
don’t differ significantly from the initial cell line by mor-
phology and pigmentation, although they have a clear 
epithelioid morphology and higher adhesion (data not 
presented). MM-4 and MM-4M2 cell lines dramatically 
differ by growth rate: doubling time at logarithmic 
phase of growth for MM-4 cells is 19.3 h, and for 
MM-4M2 line — 22.7 h; maximal density of MM-4 cell 
growth reaches 5.7 x 105/cm2, and of MM-4M2 cells — 
only 2.78 x 105/cm2 (Fig. 1).
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Fig. 1. Cell growth kinetics of MM-4 and MM-4M2 melanoma 
cell lines
The ММ-4 and ММ-4М2 cell lines are sensitive 
to  various apoptosis inducers, particularly to tumor 
necrosis factor (TNF) (Fig. 2, a, b).
Interestingly, the sensitivity to growth inhibition 
and apoptosis induction caused by TNF is much 
higher in ММ-4М2 highly metastatic subline than 
in ММ-4 cells. The difference between cell lines 
is especially expressed at TNF concentrations 
< 8–10 000 IU/ml, but at higher TNF concentrations 
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the cells of both lines become equally sensitive to TNF 
(Fig. 2, b; Fig. 3).
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Fig. 2. Apoptosis in ММ-4 (a) and ММ-4М2 (a, b) cells treated 
with TNF: a, morphology of apoptotic MM4 cells treated with TNF; 
b, DNA laddering of MM4-M2 and MM4 cells treated with TNF
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Fig. 3. Inhibition of cell growth of MM-4 and MM-4M2 mela-
noma cells
Expression of TAP1 and TAP2 in low- and high-
metastatic melanoma B16 cells. Level of metastasis 
is dependent on antigenic characteristics of tumor cells, 
and an enhanced or decreased antigenicity of dissemi-
nated tumor cells will lead to their immune recognition 
and rejection or, conversely, enhancement of metasta-
sis. TAP proteins (transporters associated with antigen 
processing) take part in the transport of oligopeptides 
from proteasomes into endoplasmic reticulum. In the 
endoplasmic reticulum these oligopeptides are bound 
to MHC class I molecules and transported to the cell 
surface. TAP proteins consist of two subunits: TAP1 and 
TAP2. It has been previously shown that TAP protein 
expression can be decreased in malignant cells, fol-
lowed by reduced protein expression or complete lack 
of MHC class I antigens on the cell surface [11, 12]. 
Thus, character of TAP proteins expression may be 
closely linked to metastatic ability of melanoma cells.
RT-PCR analysis revealed a total inhibition of mRNA 
transcription of the peptide transporter TAP1 in high-
metastatic MM-4M2 cells compared to low-metastatic 
MM-4 cells. mRNA levels of TAP2 had no significant 
differences in these melanoma sublines (Fig. 4).
TAP1 and TAP2 down-regulation in primary mela-
noma lesions is associated with the decrease of tumor 
immunogenicity and significantly correlated with tumor 
progression and development of metastases [13].
Thus, ММ-4М2 cell subline is a useful model which 
allows to reproduce post-invasive stage of hematoge-
nous metastasis, and also to examine the mechanisms 
of melanoma cell sensitivity to various programmed 
cell death inducers.
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Fig. 4. RT-PCR analysis of TAP mRNA expression in mouse 
melanoma cells with different metastatic potential
It should be noted that some characteristics of high 
metastatic MM-4M2 cells, such as a reduced rate of cell 
proliferation and increased sensitivity to TNF-induced 
apoptosis contradict, in part, to known characteristics of 
some metastatic models. It is considered that resistance 
to TNF is accompanied by an increase of the metastatic 
ability. However, in this case the sensitivity to TNF did 
not affect the selection of in vivo highly metastatic cells.
In the first part of the study we have examined the 
effect of Ukrain alone or in combination with CPM on 
the growth of ММ-4 and ММ-4М2 cell sublines [18].
The results have shown that the effect of Ukrain used 
alone or in combination with PAM differs for ММ-4 and 
ММ-4М2 cells (at least for 48 h treatment period). 
Ukrain used alone at low concentration (20 μg/ml) 
caused significant (treatment time independent) growth 
inhibition of ММ-4 cells at average by 65% (p < 0.001) 
(Fig. 5, a). In ММ-4М2 cells, the progressive inhibitory 
action of Ukrain has been observed: the number of 
viable cells decreases by 64.6% in 24 h and by 79.4% 
in 48 h (p < 0.001) (Fig. 5, b). In this case, the sensitiv-
ity of MM-4M2 cells to Ukrain was significantly higher 
(p < 0.01) than that of MM-4 cells. At high concentration 
(250 μg/ml) the drug caused death of nearly 100% cells 
of both sublines after 24–48 h of incubation.
PAM treatment of MM-4 and MM-4M2 cells influ-
enced their growth only during first 24 h of incubation, 
but not later. PAM at the low concentration (2 μg/ml) 
significantly (p < 0.01) inhibited cell growth in MM-4 cell 
line. However, at the high concentration (25 μg/ml) led to 
the increase of the number of viable cells  (see Fig. 5a). 
In MM-4M2 cells, by contrast, increased concentrations 
of PAM (from 2 to 25 ug/ml) was accompanied by a sig-
nificant decrease in the number of living cells (p < 0.01). 
The PAM, regardless of concentration after short-time 
exposure, did not change the sensitivity of both cell lines 
to the cytotoxic action of Ukrain (Fig. 5, a, b). Apoptosis 
inducing effect after prolonged treatment of MM-4 cells 
with Ukrain (48 h) in combination with PAM was more 
expressed than that after treatment with Ukraine alone.
It is known that Ukrain attenuates tumor cell growth 
by inducing arrest of the cells which are at G2/M phase 
(or G0/G1 phase in vitro) with further apoptosis induction 
[22, 23]. Analysis of cell cycle of MM-4 and MM-4M2 cells 
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treated by Ukrain in vitro has distinctly shown the ability of 
the drug to modulate the cell cycle in a dose-dependent 
way differently for the cells with various biological pro-
perties (Table). NSC-631570 did not affect apoptosis 
rate of MM-4 cells at concentration of 20 μg/ml after 
24 h of incubation. However, the number of G0/G1 cells 
increased significantly (by 56% compared to control 
cells), the number of cells in G2/M phase was 1.4 times 
lower, and S-phase cells — two times lower, what can 
point on cell cycle arrest in G0/G1. 24-hour incubation 
of MM-4 cells with Ukrain at 250 μg/ml concentration 
resulted in apoptosis of 98.4% cells.
0
20
40
60
80
100
120
140
1 2 3 4 5 6
Drugs
Vi
ab
le
 c
el
ls
, %
 o
f c
on
tro
l
MM-4
MM-4M2
0
20
40
60
80
100
120
140
1 2 3 4 5 6
Drugs
Vi
ab
le
 c
el
ls
, %
 o
f c
on
tro
l
a
b
Fig. 5. The effect of Ukrain and PAM on the growth of mouse 
melanoma cells with different biological properties: 24 h (a) and 
48 h (b): 1 — Ukrain 20 μg/ml; 2 — 250 μg/ml; 3 — PAM 2 μg/ml; 
4 — PAM 25 μg/ml; 5 — Ukrain 20 μg/ml + PAM 2 μg/ml; 6 — 
Ukrain 250 μg/ml + PAM 25 μg/ml
The MM-4M2 cells appear to be more sensitive 
to NSC-631570 at the concentration of 20 μg/ml: 
the number of apoptotic cells was 26.67% (4 times 
higher than in MM-4 cells). Moreover, the number of 
cells in G0/G1 phase has increased while the number 
of G2/M and S-phase cells has dropped. Incubation 
of MM-4M2 cells with Ukrain for 24 h at 250 μg/ml 
concentration resulted in apoptosis of 97.2% of cells.
Prolonged (for 48 h) MM-4 cells incubation with 
Ukrain at the concentration of 20 μg/ml has resulted 
in the increase of apoptotic cell number (from 1% of 
control to 25%). Apoptosis rate in MM-4M2 after 48-hour 
incubation with NSC-631570 at concentration of 20 μg/ml 
was lower than that after short-term (24-hour) exposure, 
though 15 times higher than that in the control cells. 
Ukrain caused stable apoptotic effect in both cell lines at 
the concentration of 250 μg/ml after 48 h of incubation.
Thus, melanoma cells with different metastatic po-
tential are characterized by different sensitivity to NSC-
631570. Short-term drug treatment at low concentra-
tions had caused the apoptosis of significant number 
of MM-4M2 cells only. The response of MM-4 cells 
to Ukrain had developed more slowly (after 48-hour 
of incubation). The results suggest that sensitivity of 
melanoma cells to apoptosis induced by TNF may 
coincide with sensitivity to Ukrain and possibly may 
have some common mechanisms. These biological 
patterns of the cells may be useful for the development 
of therapeutic schedule of NSC-631570 drug usage.
Table. Cell cycle distribution in low- (MM-4) and high-metastatic 
(MM-4M2) cell line after their treatment with Ukrain and PAM in vitro
Cells and 
treatment
Cell number (%) in cell cycle phases
Apoptosis G0/G1 S G2/M
Incubation for 24 h
Control ММ-4 4.73 ± 0.14 44.06 ± 2.12 30.68 ± 0.99 25.26 ± 1.94
Ukrain 20 μg/ml 5.66 ± 0.18 68.74 ± 1.60 13.39 ± 1.07* 17.87 ± 0.98*
Ukrain 250 μg/ml 98.4 + 0.06 * Apoptosis
PAM 2 μg/ml 1.13 ±0.02* 43.55 ± 1.83 32.68 ± 0.88 23.76 ± 2.00
PAM 25 μg/ml 1.66 ±0.02* 49.10 ± 1.99 32.49 ± 0.76 18.41 ± 1.34
Ukrain 20 μg/ml + 
PAM 2 μg/ml
29.2 ± 1.94* 70.15 ± 2.09* 17.16 ± 0.99* 12.69 ± 1.10*
Ukrain 
250 μg/ml + PAM 
25 μg/ml
94.46 ± 0.09* Apoptosis
Control ММ-4М2 5.61 ±0.11 44.64 ± 2.17 33.64 ± 2.01 21.72 ± 0.21
Ukrain 20 μg/ml 26.67 ± 0.79* 67.7 ± 1.60* 16.20 ± 0.98* 16.10 ± 1.04*
Ukrain 250 μg/ml 97.18 ± 0.09 Apoptosis
PAM 2 μg/ml 1.96 ± 0.07* 48.06 ± 2.98 18.49 ± 1.00 33.44 ± 1.01
PAM 25 μg/ml 6.45 ± 0.09 44.45 ± 1.06 21.20±0.86 34.34 ± 1.07
Ukrain 20 μg/ml + 
PAM 2 μg/ml
9.22 ± 0.09* 74.62 ± 1.35* 13.02 + 1.00 12.36 ± 1.01
Ukrain 
250 μg/ml + PAM 
25 μg/ml
96.82 ± 1.00* Apoptosis
Incubation for 48 h
Control ММ-4 1.06 ± 0.08 72.43 ± 3.08 15.54 ± 1.16 12.03 ± 1.10
Ukrain 20 μg/ml 24.98 ± 1.94* 66.38 ± 2.96 16.76 ± 1.12 16.86 ± 1.10*
Ukrain 250 μg/ml 97.74 ± 1.04* Apoptosis
PAM 2 μg/ml 0.61 ± 0.02* 77.20 ± 1.98 8.01 ± 1.31* 14.79 ± 1.20
PAM 25 μg/ml 0.61 ± 0.05* 78.32 ± 3.11 7.11 ± 1.12* 14.57 ± 1.22
Ukrain 20 μg/ml + 
PAM 2 μg/ml
18.73 ± 1.00* 63.95 ± 2.99 24.97 ± 
0.85 *
11.08 ± 1.02
Ukrain 
250 μg/ml + PAM 
25 μg/ml
92.51 ± 1.00* Apoptosis
Control ММ-4М2 0.58 ± 0.03 64.29 + 2.08 22.72 ± 1.55 13.00 ± 1.01
Ukrain 20 μg/ml 8.83 ± 0.99* 68.81 ±2.08 15.85 ± 1.48 15.34 ± 1.11
Ukrain 250μg/ml 83.80 ± 3.06* 63.88 + 1.77 23.41 ± 2.00 12.71 ± 3.16
PAM 2 μg/ml 0.57 ± 0.08 69.10 ± 2.68 16.06 ± 1.90 14.85 ± 1.05
PAM 25 μg/ml 0.64 ± 0.02 69.65 ± 2.41 17.53 ± 1.10 12.92 ± 1.10
Ukrain 20 μg/ml + 
PAM 2 μg/ml
14.28 ± 1.07* 72.59 ± 1.36* 14.70 ± 0.96* 12.64 ± 2.13
Ukrain 
250 μg/ml + PAM 
25 μg/ml
78.95 ± 3.03* 68.03 ± 1.42 17.54 ± 1.29 14.43 ± 1.16
*Difference is significant compared to the control (p < 0.05).
Nowadays information concerning TLR agonists effect 
on cell cycle distribution is quite scanty and controversial. 
It is known that TLR activation by natural ligands causes 
increase of malignant cell proliferation under certain con-
ditions [24, 25]. It is recently shown that TLR agonists can 
activate apoptosis of tumor cells [26]. Our experiments 
have shown that in almost all cases and regardless of the 
dose, PAM causes suppression of basal level of apop-
tosis in MM-4 cells. The PAM response pattern of MM-
4M2 subline differed from that of MM-4 cells. Exposure of 
MM-4 cells to 2 μg/ml PAM for 24 h had led to decrease 
of the apoptosis level by 65%. Usage of high PAM con-
centration (25 μg/ml) did not cause any reliable influence 
on mitotic cycle of MM-4 cells. Reliable influence on cell 
cycle was also absent when the exposure was prolonged.
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Thus, В16 melanoma cell sublines which possess 
different biological properties, had different response 
to TLR agonists. We suggest that it could be considered 
upon its usage in antitumor adjuvant immunotherapy, 
especially in the case of low metastatic tumor variant.
However, PAM treatment causes different effect on 
cell cycle in melanoma cell sublines if it used in combina-
tion with Ukrain.
Ukrain at the concentration of 20 μg/ml combined 
with PAM at the concentration of 2 μg/ml caused 
increased MM-4 tumor cell death rate. The number of 
apoptotic cells in some samples was 6 times higher in 
comparison to the control, 5 times higher compared to 
Ukrain-treated samples and 22 times higher than that 
in PAM-treated samples (see Table).
Effect of Ukrain and PAM combination (20 μg/ml 
and 2 μg/ml correspondingly) on highly metastatic MM-
4M2 cells was weaker than that of Ukrain used alone 
after shot-term exposure. However, when the exposure 
was prolonged, apoptosis inducing effect of combined 
treatment was more expressed than that after treatment 
of MM-4M2 cells with Ukrain alone.
Total apoptosis was observed in the cells of both cell 
sublines treated by combination of Ukrain and PAM at high 
concentrations (250 μg/ml and 25 μg/ml correspond-
ingly), as well as in the samples treated with Ukrain at the 
same concentration.These data have demonstrated that 
the PAM does not reduce the apoptotic effect of Ukrain.
Thus, melanoma cells with different metastatic po-
tential had different response pattern to NSC-631570 
(Ukrain) used alone or in combination with PAM. 24-hour 
treatment with drug at the low concentration resulted 
in considerable death rate of MM-4M2 cells only. 
MM-4 cells were more sensitive to combined treatment 
at low concentrations. It is possible that such effect could 
be caused by different TLR expression level in these cells.
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